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UMR_S938, Paris 6, FranceSummaryThe standard therapeutic approach currently recommended for
patients infectedwith genotype 1 hepatitis C virus (HCV) is the triple
therapy combining pegylated interferon (PEG-IFN), ribavirin (RBV)
and NS3/NS4 protease inhibitors, boceprevir or telaprevir [1]. Prote-
ase inhibitors (PIs) are direct acting antiviral drugs (DAA) which,
when added to PEG-IFN and RBV, are able to achieve a signiﬁcant
gain in terms of sustained virological response (SVR), both in naïve
and treatment-experienced patients [2–5]. The use of these new
molecules, despite its incontestable beneﬁts, reveals on the other
hand new challenges: the emergence of variants with reduced sen-
sitivity to PIs, the development of new or higher rate of side effects,
drug to drug interactions, and signiﬁcant increase in the overall cost
of antiviral therapy. Among the two DAAs commonly used in combi-
nation with PEG-IFN and RBV (PEG-IFN/RBV) for the treatment of
genotype 1 HCV patients, boceprevir has been licensed with a
lead-in phase, while telaprevir has been licensed without. EMA
approved regimens of both drugs are reported in Figs. 1 and 2. The
lead-in phase represents an initial period of 4 weeks of dual therapy
with PEG-IFN/RBV, in standard doses, followed by triple therapy. The
concept of lead-in phase was initiated by the Schering–Plough com-
pany in order to improve efﬁcacy of boceprevir-based triple therapy.
Indeed, by lowering HCV RNA level, a short course of PEG-IFN/RBV
may theoretically reduce the risk of viral breakthrough or resistance.
However, there is still much controversy regarding the utility of the
lead-in phase, some authors advocating its role in improving, and/or
predicting triple therapy effectiveness, while others view it as a use-
less complication of the therapeutic regimen, its chief disadvantage
being the inconvenience to the patient.
Lead-in phase and triple therapy effectiveness
The impact of lead-in phase on triple therapy effectiveness has
been investigated in two therapeutic trials, one in treatment-Journal of Hepatology 20
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guided therapy; IL28B, interleukin 28B.naïve, and the other in treatment-experienced patients. In treat-
ment-naïve patients, the effect of a lead-in phase of PEGIFN/RBV
therapy is based on the phase II trial SPRINT-1 evaluating boce-
previr-based triple therapy [6]. Though it was not the primary
end point, the comparison between arms with or without lead-
in phase showed no statistically signiﬁcant difference in terms
of SVR rates (66% vs. 60%, p >0.05). In terms of virological break-
through, there was a tendency of lower rate in patients treated
with lead-in (4 vs. 9%, p = 0.06). In contrast, the rate of rapid viro-
logical response at week 4 of triple therapy was signiﬁcantly
higher in patients treated with lead-in vs. no lead-in phase
(62% vs. 38%, p <0.001). According to the response-guided therapy
(RGT) regimen (Fig. 1), this result suggests that lead-in phase
might increase the number of patients eligible for a short treat-
ment duration with boceprevir based-triple therapy (28 weeks)
[2]. There are no available data regarding lead-in phase in naïve
patients receiving telaprevir-based triple therapy. In treatment-
experienced patients, the impact of lead-in phase on triple
therapy effectiveness is based on the phase III REALIZE study
evaluating telaprevir [4]. There was no difference in terms of
SVR rates between patients treated with or without a lead-in
phase, neither for previous relapsers (88% vs. 83%), nor partial
responders (54% vs. 59%) nor null responders (33% vs. 29%). Nei-
ther was virological breakthrough rate signiﬁcantly inﬂuenced by
lead-in phase (1 vs. 1% in previous relapser and 17 vs. 19% in pre-
vious non-responders). In prior relapsers, however, the rate of
rapid virological response at week 4 of triple therapy was signif-
icantly higher with lead-in vs. no lead-in phase (89 vs. 70%,
p <0.05). Because telaprevir was licensed with RGT in non-
cirrhotic relapser patients (Fig. 2), this result suggests that lead-
in may increase the percentage of patients eligible for shorter
duration treatment. In summary, there is no clear advantage of
lead-in in terms of SVR rates in patients treated with boceprevir
or telaprevir-based triple therapy. However, in patients eligible
for RGT, lead-in may shorten the duration of treatment in a sig-
niﬁcant number of cases by increasing the RVR rate on triple
therapy (Table 1). By contrast, in patients eligible for ﬁxed dura-
tion of treatment, lead-in could be avoided, including patients
receiving boceprevir-based triple therapy (Table 1).Lead-in phase as predictor: impact on therapeutic decision
In the setting of new challenges raised by the use of PIs – such as
development of viral resistance associated with treatment failure,13 vol. 58 j 391–394
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Fig. 1. EMA approved regimen of boceprevir-based triple therapy.
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Fig. 2. EMA approved regimen of telaprevir-based triple therapy.
Controversies in Hepatologyside effects or treatment cost – predictors of response to triple
therapy are highly needed. Phase 3 trials have suggested that
lead-in phase, by assessing the sensitivity to interferon, is able to
predict triple therapy effectiveness [2,4,5,7]. Post hoc analysis of
boceprevir phase III trials showed that viral load decline >1.0 log
(interferon sensitive response) or <1.0 log (poor interferon
response) at the end of lead-inwas the strongest independent pre-
dictor of SVR, in bothnaïve and treatment experiencedpatients [8].
Viral load decline was also predictive of resistant variants emer-
gence (41% in patients with <1.0 log decline vs. 6% in patients
with >1.0 log of decrease) [2,5]. However, themain issue to address
is whether viral load decline during lead-in phase is enough accu-
rate for the prediction of SVR and to have an impact on the thera-
peutic decision. In naïve patients, the relationship between viral
load decline during lead-in phase and response to triple therapy
has been investigated in the SPRINT-2 study evaluating boceprevir
[2]. Viral load decline at the end of lead-in phasewas related to the
SVR rate, since a less than 1.0 log viral load decline (poor interferon
response) was associated with a 28% SVR rate in RGT arm and 40%
in ﬁxed-duration arm, while a more than 2.0 log viral load decline
was associatedwith an SVR rate >80%. However, given its lowneg-
ative predictive value, lead-in may have no major impact on the
decision of initiating or not triple therapy in poor interferon392 Journal of Hepatology 201responders. The only decision impact could be the choice of ﬁxed
duration treatment that achieves a higher rate of SVR compared
to RGT, in this subgroup of patients [2]. On the other hand, lead-
in phase may avoid the disadvantages of triple therapy in highly-
interferon sensitive patients with rapid virological response
(RVR), i.e., HCV RNA undetectable at week 4 of lead-in. Indeed, in
this subgroup of patients, PEG-IFN/RBV was able to achieve an
SVR rate higher than 90%, similar to the SVR rates achieved with
boceprevir- or telaprevir-based triple therapy [2,3]. Therefore,
despite the lack of a randomized study, PEG-IFN/RBV could be a
therapeutic alternative to triple therapy in genotype 1 RVR
patients. There are some concerns about the duration of treatment
that is 48 weeks compared to 24 weeks with triple therapy. Only
the subgroup of RVRpatientswith lowbaseline viral loadmayben-
eﬁt from a 24-week course of PEG-IFN/RBV [9]. Another concern is
the rather small proportion of patients with RVR, less than 10%,
requiring a large number of patients to be screened. Interleukin-
28-B (IL28B) genotyping could be one way to select patients for
PEG-IFN/RBV, as more than 30% of the patients with CC genotype
may achieve an RVR [10]. Accordingly, French guidelines have pro-
posed a 4-week course of PEG-IFN/RBV prior to triple therapy
(boceprevir or telaprevir-based) in naïve patients with IL-28B CC
genotype and ﬁbrosis score 6F2 [11] (Table 1). In a recent pub-3 vol. 58 j 391–394
Table 1. Usefulness of lead-in phase in boceprevir- or telaprevir-based regimen according to patients status, naïve or treatment-experienced.
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Impact
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baseline)
Yes
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(± low viral load at baseline)
Selection of patients eligible for dual therapy
Relapsers
Lead-in Y/N
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Impact
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-
-
Yes
Non-cirrhotic
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short duration treatment
Partial responders
Lead-in Y/N No No
Null responders
Lead-in Y/N
Target population 
Impact
?
-
- 
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All
Re-evaluation of triple therapy in poor 
interferon responders
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in the setting of boceprevir-based triple therapy [12]. On the other
hand, a retrospective study from phase II telaprevir trials has sug-
gested that CC patientsmay beneﬁt from shortening triple therapy
to 12 weeks instead of the usual 24 weeks [13]. This should be con-
ﬁrmed by larger prospective studies. In treatment-experienced
patients, the accuracy of lead-in for the prediction of SVR to triple
therapy has been investigated in RESPOND-2 and PROVIDE studies
evaluating boceprevir, and in the REALIZE study evaluating tela-
previr [4,5,7]. In prior relapsers or partial responders, SVR rates
according to viral load decline <1.0 log vs. >1.0 log at the end of
lead-in were respectively 37% vs. 81% and 37% vs. 61% in the boce-
previr RESPOND-2 study and, 62% vs. 88% and 56% vs. 59% in the
telaprevir REALIZE study [4,5]. Therefore, SVR rates were rather
high, even in poor interferon responders, suggesting that lead-in
may have no major impact on treatment decision, i.e., initiating
or not triple therapy, in prior relapsers or partial responders. In
prior null responders, SVR rates according to viral load decline <1.0
log vs. >1.0 log at the endof lead-inwere respectively 36% vs.55% in
the boceprevir PROVIDE study and 15% vs. 54% in the telaprevir
REALIZE study [4,7]. In the REALIZE study, the relatively low SVR
rate in poor interferon responders, i.e., 15%, may question the use
of telaprevir in this very difﬁcult-to-treat population. It should
be noted that about half of the patients had severe ﬁbrosis, a base-
line parameter also highly predictive of SVR in prior null respond-
ers. Indeed, the SVR rate was lower that 10% in case of extensive
ﬁbrosis associatedwithpoor interferon response. In the boceprevir
PROVIDE study, the higher SVR rate in poor interferon responders,Journal of Hepatology 201i.e., 36%, could be explained by the small proportion of patients
with severe ﬁbrosis. Moreover, the small sample size population
could hamper the interpretation of the results. In summary, lead-
in phase is a good predictor of SVR to triple therapy in treatment
experienced patients but may have no major impact on therapeu-
tic decision, except in prior null responders (Table 1). In this sub-
group of patients, lead-in seems to have some advantages, at
least for the decision of initiating telaprevir-based triple therapy,
and the beneﬁt-risk ratio should be re-evaluated in case of poor
interferon response. In patients with undetermined previous
response proﬁle, lead-in phase might be informative for reclassiﬁ-
cation, but ﬁnally without any signiﬁcant impact on therapeutic
decision.Lead-in phase and tolerance with triple therapy
By testing the tolerance to PEG-IFN/RBV prior to initiating triple
therapy, lead-in phase could be helpful for the management of
patients, especially in cirrhotics. The French CUPIC study reported
a high risk of serious adverse events, including death, in this pop-
ulation when exposed to triple therapy [14]. The lead-in phase
may permit dosage adjustment of PEG-IFN and RBV according
to clinical tolerance, especially hematological toxicity, as well
as the initiation, if needed, of growth factors, prior to introducing
triple therapy. In a randomized trial evaluating the management
of anemia in boceprevir-treated patients, RBV dosage adjust-
ments as ﬁrst line during lead-in phase had no major impact on3 vol. 58 j 391–394 393
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SVR rate, compared to EPO use [15]. These results should be tem-
pered by the fact that less than 10% of the patients had cirrhosis,
and by the notable decrease of SVR rate in patients with severe
ﬁbrosis randomized in the RBV arm. Speciﬁc studies are needed
in cirrhotic patients prior to draw deﬁnitive conclusions. More-
over, we do not know whether PEG-IFN/RBV dosage adjustment
during lead-in phase has a different impact on SVR compared
to dosage adjustment during triple therapy.Lead-in phase, practical issues and cost-effectiveness
There are important practical issues that argue against the use of
the lead-in phase, as the increase in the total duration of treat-
ment (minimal duration of 28 weeks in naïve patients), the
inconvenience to the patient, who is subjected to an initial period
of 4 weeks of PEG-IFN/RBV therapy requiring an additional visit
and blood sample test at the end of lead-in. Thus, the lead-in
phase may complicate the therapeutic scheme, both for the
patient and for the physician. Another important practical issue
is the short delay required for HCV RNA results at the end of
lead-in phase, in case of treatment decision. Along with practical
issues of therapy also comes an increased overall treatment cost,
which, when added to the cost of antiviral therapy using PIs, may
result in a less favorable cost/beneﬁt proﬁle. Until now, the lead-
in strategy was validated as cost-effective regarding the selection
for dual therapy of naïve genotype 1 patients with ﬁbrosis score
F2 in the setting of boceprevir-based triple therapy [12]. Indeed,
selective treatment strategy guided by RVR in naïve patients was
cost-effective compared to universal boceprevir-response guided
therapy. In the setting of telaprevir-based triple therapy, selective
treatment strategy guided by the IL-28B genotype was also cost-
effective but the lead-in strategy was not evaluated. The authors
recommend using PI-free strategies as ﬁrst-line therapy in
patients with IL28B CC genotype or in those who achieve RVR.
Cost-effectiveness analysis of selective treatment strategies in
prior null responders needs further consideration.Conclusions
In conclusion, lead-in phase with PEG-IFN/RBV offers no clearly
proven virological beneﬁt, except a shorter duration of treatment
in non-cirrhotic naïve patients receiving boceprevir-based regi-
men or in relapsers receiving telaprevir-based regimen. In view
of its value for the prediction of triple therapy effectiveness,
lead-in phase should be considered in two subgroups of patients:
(1) those who could beneﬁt from a 24-week course of PEG-IFN/
RBV, i.e., low viral load at baseline, with CC IL-28B genotype
and mild liver disease 6F2, (2) those who are poor interferon
responders, especially prior null responders in whom initiation
of triple therapy should be re-evaluated. An additional beneﬁt
would be the possibility of tailoring PEG-IFN/RBV dosage during
the lead-in phase in patients with poor tolerance, but this strat-
egy needs additional investigations, especially in cirrhotics. For
all the other categories of patients, there is no clear evidence that
justiﬁes the use of lead-in phase. In the approaching era of more394 Journal of Hepatology 201efﬁcient therapeutic regimens in chronic hepatitis C, it is proba-
ble that the terms of this controversy will be no longer relevant.Conﬂict of interest
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